Cytokinetics Incorporated (NASDAQ:CYTK) and Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Navidea Biopharmaceuticals Inc||1.17M||29.52||16.16M||-0.12||0.00|
Table 1 highlights Cytokinetics Incorporated and Navidea Biopharmaceuticals Inc’s gross revenue, earnings per share and valuation.
Table 2 has Cytokinetics Incorporated and Navidea Biopharmaceuticals Inc’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Navidea Biopharmaceuticals Inc||-1,381.20%||-355.9%||-119.6%|
Risk and Volatility
Cytokinetics Incorporated is 104.00% more volatile than Standard & Poor’s 500 because the company has a beta of 2.04. Navidea Biopharmaceuticals Inc’s 18.00% less volatile than Standard & Poor’s 500 volatility due to the company’s 0.82 beta.
Cytokinetics Incorporated and Navidea Biopharmaceuticals Inc Recommendations and Ratings are available in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Navidea Biopharmaceuticals Inc||0||0||0||0.00|
The consensus target price of Cytokinetics Incorporated is $15, with potential upside of 71.04%.
Insider & Institutional Ownership
The shares of both Cytokinetics Incorporated and Navidea Biopharmaceuticals Inc are owned by institutional investors at 73.6% and 5.5% respectively. Cytokinetics Incorporated’s share owned by insiders are 0.4%. On the other hand, insiders owned about 12.3% of Navidea Biopharmaceuticals Inc’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Navidea Biopharmaceuticals Inc||1.15%||1.95%||-14.36%||-4.02%||-53.27%||62.68%|
For the past year Cytokinetics Incorporated has weaker performance than Navidea Biopharmaceuticals Inc
Cytokinetics Incorporated beats Navidea Biopharmaceuticals Inc on 7 of the 11 factors.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis. Tirasemtiv has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency. The company is preparing for the commercialization of Tirasemtiv in North America and Europe, as well as has granted an option to Astellas Pharma Inc. for development and commercialization in other countries. The company has strategic alliances with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator that is in two ongoing Phase II clinical trials enrolling patients with spinal muscular atrophy and chronic obstructive pulmonary disease, as well as other indications associated with muscle weakness; and with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, which is in Phase III clinical trial in patients with heart failure. Amgen Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and other countries; and Astellas Pharma Inc. holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil and related compounds. The company was founded in 1997 and is headquartered in South San Francisco, California.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California, San Diego. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.